This article is more than 5 years old. Information may no longer be current.

MC2 Therapeutics’ dry eye treatment demonstrates positive phase 2 results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MC2-03, a treatment candidate from MC2 Therapeutics, showed clinical improvement in moderate to severe dry eye patients in the phase 2 MC2-03-C1 Northern Lights trial, according to a press release.

MC2-03 (PADciclo) is an eye drop containing ciclosporin and formulated using the company’s proprietary PAD technology.

The randomized, double-masked, parallel arms, controlled 6-month study included 263 dry eye patients in two active treatment arms, MC2-03 0.06% ciclosporin and MC2-03 0.03% ciclosporin, which were compared with two control arms, MC2-03 vehicle and lubricant, the release said.

Both treatment arms showed “a similar and consistent trend for a higher proportion” of corneal fluorescein staining improvement after 6 months compared with control arms, the release said. In addition, the severe population benefited more from active treatment, with more of those patients being corneal fluorescein staining responders compared with the control arm, according to the results.

“The results of the MC2-03-C1 Northern Lights trial are positive and extremely promising, especially in the most severe population where results go beyond our initial expectations,” MC2 President Jesper J. Lange said in the release.